Biology:SCB-2019
From HandWiki
Revision as of 20:20, 24 October 2021 by imported>WikiGary (add)
Short description: Vaccine candidate against COVID-19
| Vaccine description | |
|---|---|
| Target disease | SARS-CoV-2 |
| Type | Protein subunit |
| Clinical data | |
| Routes of administration | Intramuscular |
| Identifiers | |
| DrugBank | |
SCB-2019 is a COVID-19 vaccine candidate developed by Clover Biopharmaceuticals.[1][2][3]
References
- ↑ "SCB-2019 as COVID-19 Vaccine". United States National Library of Medicine. 28 May 2020. https://clinicaltrials.gov/ct2/show/NCT04405908.
- ↑ "Clover Biopharmaceuticals starts Phase I Covid-19 vaccine trial". Clinical Trials Arena. 20 June 2020. https://www.clinicaltrialsarena.com/news/clover-vaccine-covid-19-trial/.
- ↑ "A Controlled Phase 2/3 Study of Adjuvanted Recombinant SARS-CoV-2 Trimeric S-protein Vaccine (SCB-2019) for the Prevention of COVID-19 (SCB-2019)". United States National Library of Medicine. https://clinicaltrials.gov/ct2/show/study/NCT04672395.
External links
 |
